Xgeva (Prostate Cancer) - Forecast and Market Analysis to 2022


#163792

49pages

GlobalData

$ 6995

In Stock

Xgeva (Prostate Cancer) - Forecast and Market Analysis to 2022

Summary

GlobalData has released its new PharmaPoint Drug Evaluation report,  Xgeva (Prostate Cancer) - Forecast and Market Analysis to 2022. The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J’s Zytiga (abiraterone acetate) and Medivation/Astellas’ Xtandi (enzalutamide) will drive strong market growth over the next decade. 

These safe and orally administered treatments will provide safety and convenience benefits over the current standard of care, chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC. The December 12, 2012 FDA approval of Zytiga for the added indication of chemotherapy-naïve mCRPC marks the onset of a new treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy and beyond. For patients with earlier-stage prostate cancer, androgen deprivation therapy with LHRH agonists and first-generation antiandrogens remains the standard of care for suppressing testosterone levels and temporarily controlling the disease.

Prostate cancer frequently metastasizes to the bones, increasing the likelihood of skeletal fractures. Amgen’s Xgeva is a human Monoclonal Antibody (mAb) that binds to RANKL, a protein produced by osteoclasts involved in bone resorption, and prevents it from activating its receptor, RANK, on the osteoclast surface. This prevents the osteoclasts from breaking down bone and causing SREs (Xgeva Prescribing Information, 2010).

Scope
  • Overview of Prostate cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Xgeva including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Xgeva for the top nine countries from 2012 to 2022.
  • Sales information covered for the US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia 
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Prostate cancer
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Xgeva performance 
  • Obtain sales forecast for Xgeva from 2012-2022 in nine markets (US, Japan, UK, France, Germany, Spain, Italy , Canada, and Australia)
Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 10

3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 11
3.1.3 Prognosis 12
3.1.4 Quality of Life 13
3.2 Symptoms 14

4 Disease Management 15
4.1 Diagnosis and Referral Overview 15
4.2 Treatment Overview 17
4.2.1 Conservative Management Strategies 22
4.2.2 Localized Treatments 23
4.2.3 Hormone Therapy 24
4.2.4 Drug Therapies 26

5 Competitive Assessment 28
5.1 Overview 28
5.2 Strategic Competitor Assessment 29

6 Xgeva (denosumab) 32
6.1 Overview 32
6.2 Efficacy 33
6.3 Safety 34
6.4 SWOT Analysis 34
6.5 Forecast 35

7 Appendix 37
7.1 Bibliography 37
7.2 Abbreviations 41
7.3 Methodology 42
7.4 Forecasting Methodology 42
7.4.1 Number of Prostate Cancer Patients Currently Seeking Treatment 43
7.4.2 Percent Drug-treated Patients 43
7.4.3 Percent Hormone Therapy-Treated Patients 43
7.4.4 General Pricing Assumptions 44
7.4.5 Individual Drug Assumptions 45
7.4.6 Generic Erosion 46
7.5 Physicians and Specialists Included in This Study 46
7.6 Survey of Prescribing Physicians 47
7.7 About the Authors 48
7.7.1 Authors 48
7.7.2 Global Head of Healthcare 48
7.8 About GlobalData 49
7.9 Contact Us 49
7.10 Disclaimer 49

Table 1: Stage Distribution of Prostate Cancer at Diagnosis in Selected Major Markets 13
Table 2: Global Variations in Recommendations on Routine PSA Screening 15
Table 3: Most Commonly Followed Treatment Guidelines for Prostate Cancer, 2012 18
Table 4: Most Commonly Prescribed Drugs for Prostate Cancer by Class in the Global Markets, 2012 21
Table 5: Leading Treatments for Prostate Cancer, 2012 31
Table 6: Product Profile - Xgeva 33
Table 7: Xgeva SWOT Analysis, 2012 35
Table 8: Global Sales Forecasts ($m) for Xgeva, 2012-2022 36
Table 9: Physicians Surveyed, By Country 47
Figure 1: General Treatment Algorithm for Prostate Cancer, 2012 20